CCMU
ABOS icon

Cheyne Capital Management (UK)’s Acumen Pharmaceuticals ABOS Stock Holding History

Cheyne Capital Management (UK)’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-55,829
Closed -$301K – 23
2022
Q4 		$301K Buy
+55,829
New +$375K 0.53% 47

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Cheyne Capital Management (UK)'s ABOS Position: Q1 2023 in Review

Cheyne Capital Management (UK) sold out of Acumen Pharmaceuticals (ABOS) in Q1 2023, closing a stake of 55,829 shares — an estimated $301K sold.

Cheyne Capital Management (UK) first reported a position in ABOS in Q4 2022 and held it in 1 quarter. The position peaked at $301K in Q4 2022. 61 funds tracked by Wall St. Rank hold ABOS as of Q1 2023.

  • Cheyne Capital Management (UK) reported no remaining Acumen Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 55,829 Acumen Pharmaceuticals shares in Q1 2023, an estimated $301K.
  • Cheyne Capital Management (UK) first reported a position in Acumen Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Cheyne Capital Management (UK)'s Acumen Pharmaceuticals position peaked at $301K in Q4 2022.
  • 61 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2023.

Based on Cheyne Capital Management (UK)'s 13F filing for Q1 2023, filed 3 May 2023.